Open Access
CC BY-NC-ND 4.0 · Horm Metab Res 2023; 55(08): 511-519
DOI: 10.1055/a-2112-1596
Review

Pharmacological Interventions for Glucocorticoid-Induced Osteoporosis: An Umbrella Review

Haodong Liang
1   The Affiliated TCM Hospital of Guangzhou Medical University, Guangzhou, China
,
Jinlong Zhao
1   The Affiliated TCM Hospital of Guangzhou Medical University, Guangzhou, China
,
Tianzhao Tian
1   The Affiliated TCM Hospital of Guangzhou Medical University, Guangzhou, China
› Institutsangaben

Funding Information Health Technology Project of Guangzhou — No. 20222A010019 Administration of Traditional Chinese Medicine of Guangdong Province — No. 20221323
Preview

Abstract

There is still a lack of high-quality evidence-based studies on the efficacy of drug treatment for glucocorticoid-induced osteoporosis (GIOP). The purpose of this umbrella review is to comprehensively evaluate the existing evidence to determine the efficacy and safety of pharmacological interventions for GIOP. We searched PubMed, Embase, and the Cochrane Library for systematic reviews and/or meta-analyses (SRs) of randomized controlled trials (RCTs) aimed at evaluating drug therapy for GIOP. Both the methodological quality and the strength of recommendation of the endpoints included in the SRs were evaluated by using the AMSTAR-2 tool and GRADE system, respectively. Six SRs involving 7225 GIOP patients in 59 RCTs were included in this umbrella review. The results of the methodological quality evaluation showed that 2 high-quality, 2 low-quality and 2 critically low-quality SRs were included. The GRADE evaluation results showed that the quality of evidence and the strength of recommendation of 46 outcome indicators were evaluated in the umbrella review; there were 3 with high-level evidence, 20 with moderate-level evidence, 15 with low-level evidence, and 8 with very low-level evidence. Moderate- to high-level evidence suggests that teriparatide, bisphosphonates, and denosumab can improve the bone mineral density in patients with GIOP. The findings of this umbrella review can enable patients and clinical healthcare professionals to choose the best drug prescription.



Publikationsverlauf

Eingereicht: 15. Mai 2023

Angenommen nach Revision: 19. Juni 2023

Accepted Manuscript online:
19. Juni 2023

Artikel online veröffentlicht:
31. Juli 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany